Publications by authors named "Leonie C S De Vries"
Background And Aims: Histological outcomes and JAK-STAT signalling were assessed in a prospective ulcerative colitis [UC] patient cohort after 8 weeks treatment with tofacitinib, an oral Janus kinase [JAK] inhibitor.
Methods: Forty UC patients received tofacitinib 10 mg twice daily for 8 weeks. Treatment response was defined as histo-endoscopic mucosal improvement [HEMI].
Article Synopsis
- TYK2, a key player in the signaling of cytokines, is critical for the development of inflammatory bowel disease (IBD), and a selective inhibitor (TYK2i) was tested for its effectiveness in treating it in a mouse model of colitis.
- In the study, TYK2i significantly reduced weight loss and disease severity in mice with colitis, while T cells lacking TYK2 activity also showed reduced disease symptoms.
- The findings suggest that targeting TYK2 could be a promising approach for IBD treatment, as it decreased specific immune responses both in mice and human T cells.
Tofacitinib, a non-selective Janus kinase (JAK) inhibitor, is effective in inducing clinical and endoscopic remission in patients with active ulcerative colitis (UC). Tofacitinib inhibits cytokine signalling through blockade of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). Adverse events including neutropenia and anaemia resulting from JAK2 inhibition have been observed in actively treated patients.
View Article and Find Full Text PDFObjective: To assess whether exercise training in adult patients with a systemic right ventricle (RV) improves exercise capacity and quality of life and lowers serum N-terminal prohormone brain natriuretic peptide (NT-proBNP) levels.
Design: Multi-centre parallel randomized controlled trial.
Participants: Patients with a systemic RV due to congenitally or surgically corrected transposition of the great arteries.